Shi Wei-yun, Zeng Qing-yan, Li Shao-wei, Xie Li-xin
Shandong Eye Institute & Hospital, Qingdao 266071, China.
Zhonghua Yan Ke Za Zhi. 2003 Nov;39(11):678-82.
To study the indication and incision of phacoemulsification and intraocular lens (IOL) implantation after high-risk penetrating keratoplasty (PKP) and to evaluate the clinical results.
Twenty-six eyes of 25 patients who underwent high-risk PKP were treated with phacoemulsification and IOL implantation. The high-risk reasons included chemical burn of cornea, severe infective corneal perforation, total keratoplasty, diameter of the corneal graft larger than 8.5 mm, secondary keratoplasty and PKP combined with cataract extraction and anterior segment vitrectomy. Systemic and local steroid administration was given and surgical indication and incision were chosen according to the condition of the eyes. The mean interval time between PKP and IOL implantation was 11 months. Visual acuity, refractive status, central corneal endothelial cell density before and after IOL implantation (3 months) and allograft rejection were recorded. The mean follow-up after IOL placement was 17 months.
Uncorrected visual acuity was 50/100 or better in 7 (27%) eyes and corrected visual acuity was 50/100 or better in 12 (46%) eyes. Fourteen (54%) eyes had refractive errors within 2 diopters. The mean refractive cylinders before and after IOL implantation were 5.70 D and 4.70 D, respectively (paired t test, t = 1.471, P = 0.154). The endothelial cell density before and after IOL implantation was 1883 cells/mm(2) and 1760 cells/mm(2), respectively (t = 1.934, P = 0.065) and the rate of endothelial cell loss was 6.5%. Only one graft rejection (4%) occurred 7 months after IOL implantation (anterior chamber IOL).
It is safe and effective to perform phacoemulsification and IOL implantation after high-risk PKP when paying attention to the perioperative treatment and selecting the surgical indication and the position of the incision.
研究高危穿透性角膜移植术(PKP)后白内障超声乳化吸除联合人工晶状体(IOL)植入术的适应证及切口,并评估临床效果。
对25例接受高危PKP的患者的26只眼行白内障超声乳化吸除联合IOL植入术。高危原因包括角膜化学伤、严重感染性角膜穿孔、全角膜移植、角膜植片直径大于8.5 mm、再次角膜移植以及PKP联合白内障摘除及前段玻璃体切除术。给予全身及局部类固醇药物治疗,并根据眼部情况选择手术适应证及切口。PKP与IOL植入的平均间隔时间为11个月。记录IOL植入前后(3个月)的视力、屈光状态、中央角膜内皮细胞密度及移植排斥反应。IOL植入后的平均随访时间为17个月。
7只眼(27%)的裸眼视力为50/100或更好,12只眼(46%)的矫正视力为50/100或更好。14只眼(54%)的屈光不正度数在2屈光度以内。IOL植入前后的平均散光度数分别为5.70 D和4.70 D(配对t检验,t = 1.471,P = 0.154)。IOL植入前后的内皮细胞密度分别为1883个细胞/mm²和1760个细胞/mm²(t = 1.934,P = 0.065),内皮细胞丢失率为6.5%。仅1例(4%)发生移植排斥反应,于IOL植入后7个月出现(前房型IOL)。
高危PKP后行白内障超声乳化吸除联合IOL植入术时,注意围手术期处理并选择合适的手术适应证及切口位置是安全有效的。